After a long struggle, the law on tax-based research incentives in the form of a tax-free research allowance came into force on January 1, 2020. This can benefit not only established companies but also startups. The associated regulations have been implemented and updated in recent months.
The speakers from BIO Deutschland and EY will use their first-hand experience to explain the basics, possibilities and limitations and provide an initial report from the companies' perspective.
Learning objective
In this seminar, you will receive all the necessary information from a strategic perspective to evaluate the benefits of the FZulG for your company and to optimally prepare yourself for submitting an application at the end of the year.
Focus
- Assessment of the law from a biotech and pharmaceutical perspective, advantages and disadvantages of the regulations
- Basic facts on the legal right to research and development funding
- R&D according to the AGVO with practical examples
- What do companies need to prepare to successfully apply for the tax-free research allowance?
